A new international clinical trial,MK-2870, is now open for women with recurrent or metastatic cervical cancer who have already received standard treatment. This study is exploring a promising new treatment called sacituzumab tirumotecan (MK-2870) to see if it can help women live longer and feel better compared to current second-line therapies.

Women in Ireland can participate in this trial at Mater Misericordiae University Hospital (MMUH) in Dublin.

Why This Trial Matters

When cervical cancer returns or spreads after initial treatment, treatment options can be limited. Standard second-line therapies don’t work well for everyone, and many patients are looking for more effective treatments.

Sacituzumab tirumotecan (MK-2870) is a targeted cancer therapy called an antibody-drug conjugate (ADC). An ADC is like a "smart bomb" for cancer treatment. It combines:

• An antibody — a protein designed to recognize and bind to specific markers on cancer cells
• A powerful chemotherapy drug

The antibody targets a protein called TROP2 found on the surface of many cancer cells, delivering the chemotherapy directly to the cancer while sparing most healthy cells. This targeted approach aims to increase treatment effectiveness and reduce side effects.

Many cervical cancers have the TROP2 protein on their surface, making this treatment potentially very precise and effective.

Who Can Join the Trial?

You may be eligible if:

• You are a woman aged 18 or older.
• You have cervical cancer that has come back or spread.
• You’ve already had one line of chemotherapy and immunotherapy (such as pembrolizumab or similar drugs).
• Your cancer is still growing despite treatment.
• You are well enough to carry out most of your normal activities (ECOG performance status 0–1).

Your oncology team can help determine if you qualify and if the trial is right for you.

What Does the Study Involve?

If you join the trial, you will be randomly assigned to one of two groups:

1. Study drug (sacituzumab tirumotecan) — given through an IV every 2 weeks
2. Standard treatment chosen by your doctor — options may include drugs like topotecan, gemcitabine, or others

Doctors will monitor how your cancer responds through scans, blood tests, and symptom tracking. The study will also assess how treatment affects your quality of life, including physical and emotional wellbeing.

The research team will provide all the information you need about possible benefits and risk to make an informed decision.

Interested in Joining?

If you're interested or want to learn more, please speak with your oncologist or cancer care team. They can help assess your eligibility and discuss whether this trial is suitable for you.

Trial Location in Ireland:

Mater Misericordiae University Hospital (MMUH)
Eccles Street, Dublin 7

MMUH is a leading teaching hospital with extensive experience in cancer care and clinical trials.